Symbol="IOVA"
AssetType="Common Stock"
Name="Iovance Biotherapeutics Inc"
Description="Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California."
CIK="1425205"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="999 SKYWAY ROAD, SUITE 150, SAN CARLOS, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="1558517000"
EBITDA="-417380000"
PERatio="None"
PEGRatio="0"
BookValue="2.575"
DividendPerShare="0"
DividendYield="0"
EPS="-1.99"
RevenuePerShareTTM="0.001"
ProfitMargin="0"
OperatingMarginTTM="-1799.89"
ReturnOnAssetsTTM="-0.391"
ReturnOnEquityTTM="-0.797"
RevenueTTM="238000"
GrossProfitTTM="0"
DilutedEPSTTM="-1.99"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="24.55"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="2.774"
EVToRevenue="-"
EVToEBITDA="-2.187"
Beta="0.0942"
num_52WeekHigh="11.95"
num_52WeekLow="5.28"
num_50DayMovingAverage="7.54"
num_200DayMovingAverage="7.08"
SharesOutstanding="247777000"
DividendDate="None"
ExDividendDate="None"
symbol="IOVA"
open="6.12"
high="6.38"
low="6.00"
price="6.29"
volume="2904003.00"
latest_trading_day="2023-08-21"
previous_close="6.07"
change="0.22"
change_percent="3.6244%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="41"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="59"
Volume_recent_avg="5287042"
Change_recent_avg="-0.02"
Delta_recent_avg="0.44"
Variance_recent_avg="0.22"
Change_ratio_recent_avg="-0.32"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="59"
Aroon_momentum_negative="41"
image_negative_thumbnail_id_1="517"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0088.jpeg"
image_negative_thumbnail_id_2="490"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0115.jpeg"
image_neutral_thumbnail_id_1="553"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0046.jpeg"
image_neutral_thumbnail_id_2="557"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0042.jpeg"
image_positive_thumbnail_id_1="684"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0024.jpeg"
image_positive_thumbnail_id_2="952"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0114.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1181"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0015.jpeg"
